Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q4 2016 (← Previous) (Next →)

Filing Date: Jan 18, 2017

Total Value ($000): $102,740,818 (100.0% shares, 0.0% debt)

Holdings (7)

— Audentes Therapeutics, Inc. 32.1%

Value ($000) $33,010,821 Shares 1,806,832 Est. Cost $17810.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 18.0%

Value ($000) $18,542,764 Shares 2,215,384 Est. Cost $20.09 Unrealized -61.4%

— Clovis Oncology, Inc. 17.6%

Value ($000) $18,097,419 Shares 407,416 Est. Cost $56000.00 Unrealized —

— Achaogen, Inc. 16.2%

Value ($000) $16,680,599 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— ImmuneDesign Corp. 11.8%

Value ($000) $12,145,155 Shares 2,208,210 Est. Cost $7580.00 Unrealized —

GKOS Glaukos Corporation 2.4%

Value ($000) $2,449,980 Shares 71,428 Est. Cost $30.09 Unrealized +13.8%

— CymaBay Therapeutics, Inc. 1.8%

Value ($000) $1,814,080 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Audentes Therapeutics, Inc.	1,806,832	$33,010,821	32.1%	$17810.00	—	Common Stock	05070R104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$18,542,764	18.0%	$20.09	-61.4%	Common Stock	67576A100
—	Clovis Oncology, Inc.	407,416	$18,097,419	17.6%	$56000.00	—	Common Stock	189464100
—	Achaogen, Inc.	1,281,152	$16,680,599	16.2%	$13050.00	—	Common Stock	004449104
—	ImmuneDesign Corp.	2,208,210	$12,145,155	11.8%	$7580.00	—	Common Stock	45252L103
GKOS	Glaukos Corporation	71,428	$2,449,980	2.4%	$30.09	+13.8%	Common Stock	377322102
—	CymaBay Therapeutics, Inc.	1,048,601	$1,814,080	1.8%	$9830.00	—	Common Stock	23257D103